STOCK TITAN

AVAI BIO (AVAI) Stock News

AVAI OTC

Welcome to our dedicated page for AVAI BIO news (Ticker: AVAI), a resource for investors and traders seeking the latest updates and insights on AVAI BIO stock.

Avaí Bio, Inc. develops cell-based therapies centered on genetically modified cell lines, protective encapsulation technologies and joint venture or licensing structures. The company, formerly Avant Technologies Inc., uses the AVAI ticker and has described a biotechnology focus spanning diabetes, age-related disorders and anti-aging applications.

Recurring developments include the Insulinova diabetes program, which pairs insulin-producing or regulating cells with encapsulation technology, and the Klothonova α-Klotho program, which uses encapsulated cells designed to produce the longevity protein α-Klotho. Company updates also cover GMP manufacturing steps such as master cell bank production, research presentations, partner collaborations and the completed corporate name change to Avaí Bio.

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) released a progress report detailing their advancements in AI supercomputer-driven data centers. CEO William Hisey highlighted the company's strategy to address cost and performance challenges in AI and big data industries. Key milestones include entering a partnership with Wired4Tech in February 2024, planning the construction of an AI data center in Milwaukee for 2025, and implementing a Zero Trust Architecture for enhanced security. In May 2024, Avant announced equipping its data centers with High-Performance Computing (HPC) systems and developing a proprietary AI software platform. Most recently, Avant signed a $50 million agreement to acquire 50 high-performance immersible servers from Flow Wave, , aiming to lead in distributed submerged infrastructure solutions. These developments position Avant at the forefront of AI and data center management, promising reduced latency, improved security, and increased scalability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
AI
-
Rhea-AI Summary

Avant Technologies announced a Binding Letter of Intent (BLOI) with Flow Wave to acquire up to 50 high-performance immersible AI-powered servers for $50 million. This deal aims to enhance Avant's capabilities in AI and data center infrastructure, featuring immersion cooling technologies for improved performance and energy efficiency. The servers will support intensive AI and machine learning workloads, optimizing resource allocation and reducing costs. The acquisition aligns with Avant's commitment to innovation and sustainability, positioning the company at the forefront of the AI infrastructure market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
AI
-
Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) announced its collaboration with Wired4Tech to assess the performance of a next-gen AI server for its AI data center cloud infrastructure. Wired4Tech will conduct comprehensive benchmarking, evaluating metrics such as response time, throughput, CPU and memory usage, disk I/O, network latency, error rates, power consumption, and cost savings. This aims to validate the server's efficiency in handling complex AI workloads. CEO William Hisey emphasized the importance of this initiative in advancing Avant's AI infrastructure business strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
AI
Rhea-AI Summary

Avant Technologies announced plans to develop a proprietary AI software platform for next-generation data centers. This platform will use machine learning to analyze data, predict resource needs, and make real-time allocation decisions, enhancing data center management. The AI software will manage data ingestion, cleaning, transformation, and storage, and translate AI recommendations into actionable insights. The company aims to optimize resource utilization and performance while minimizing human intervention. Avant is assessing open-source frameworks like TensorFlow and PyTorch to complement its proprietary algorithms, enhancing compatibility with various AI tools and libraries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.87%
Tags
AI
-
Rhea-AI Summary

Avant Technologies, Inc. announced plans to equip its AI-managed data center with High-Performance Computing (HPC) systems, showcasing its commitment to advancing AI capabilities. The facility will feature cutting-edge technology, AI-driven management, and security measures to handle complex AI workloads efficiently. Avant aims to accelerate AI advancements, streamline development processes, and provide tailored solutions for clients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
AI
-
Rhea-AI Summary

Avant Technologies, Inc. (OTCQB: AVAI) has appointed William Hisey as the new CEO following the acquisition of Wired4Health, a healthcare technology and data integration firm. Hisey brings 25 years of business operations and finance experience to drive the company's growth in the AI industry. Avant has been strategically positioning itself for growth in AI data center infrastructure development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
management acquisition
Rhea-AI Summary

Avant Technologies, Inc. (AVAI) plans to implement a Zero Trust Architecture (ZTA) framework powered by AI in its data centers to enhance security for customer data. The integration of AI with ZTA aims to boost security, optimize data center operations, and provide cost-effective solutions. The move aligns with Avant's commitment to innovation and technology for business optimization and security.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.72%
Tags
AI
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.24%
Tags
AI
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.83%
Tags
AI
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
AI

FAQ

What is the current stock price of AVAI BIO (AVAI)?

The current stock price of AVAI BIO (AVAI) is $0.12564 as of July 6, 2026.

What is the market cap of AVAI BIO (AVAI)?

The market cap of AVAI BIO (AVAI) is approximately 17.3M.